Three new species of Entomobryinae (Collembola, Entomobryidae) from Gansu, China.

Three new species of Entomobryidae are described here. Willowsia trifascia sp. nov. is mainly characterised by its three longitudinal blue stripes on body and chaetotaxy of dorsal head. Himalanura gansuensis sp. nov. is the second species of the genus reported from China and characterised by its chaetotaxy, such as nine macrochaetae on Abd. I, and denticle on labral papilla. Homidia maijiensis sp. nov. is characterised for its yellow-green ground colour, labial base chaetae and dental spines.

A new species of Entomobrya (Collembola: Entomobryidae) from the Northeast China and first record of Entomobryoides sotoadamesi.

A new species of Entomobrya Rondani: E. tristriata sp. nov., from Jilin, one province of the Northeast China and first record of Entomobryoides sotoadamesi Jordana, Potapov Baquero, 2011, are herein described. Entomobrya tristriata sp. nov. is characterised by three longitudinal dark blue stripes from Th. II to Abd. III, prelabral smooth chaetae and larger subapical tooth on mucro. However, in most species of Entomobrya, prelabral chaetae are ciliated and subapical tooth is subequal to the apical one. Entomobryoides sotoadamesi was first described from Far East of Russia and Chinese specimens agree with the original description.

Revision of Tomocerus similis Chen & Ma, with discussion of the kinoshitai complex and the distal tibiotarsal chaetae in Tomocerinae (Collembola, Tomoceridae).

Molecular analysis and a detailed morphological comparison revealed that Tomocerus similis Chen & Ma was described from individuals belonging to several species from several localities. Based on both old and new material from Anhui and Jiangsu Provinces, China, T. similis is redescribed and two new species are described. The three species are morphologically similar. Tomocerus persimilis sp. nov. differs from the others by the presence of central macrochaeta on head and of several distinct distal inner teeth on unguis. Tomocerus dissimilis sp. nov. is characterised by pointed tenent hairs on anterior legs. Remarks are made on the systematics and ecology of the kinoshitai complex, and on the taxonomic value of tenent hair and its adjacent chaetae.

Two new species of Willowsia (Collembola: Entomobryidae) from Guizhou Province, China.

The genus Willowsia Shoebotham, 1917 belongs to the family Entomobryidae. Within the family it is characterised by having 4-segmented antennae, 8+8 eyes, spines and scales absent from dens, claw with unpaired inner teeth, bidentate mucro and scales on body. Twenty-six species have been described in the genus worldwide including eight species from China. Two new species, Willowsia pseudoshi sp. nov. and W. variabilis sp. nov., from China are described here. The former species has pale yellow antennae except for distal part of Antenna IV which has some blue pigment and 4 macrochaetae are present on Abdomen I. The latter species has the whole antenna pigmented blue and 7-8 macrochaetae present on Abdomen I. A key to Chinese species of Willowsia is given.

Biodegradable Polymer-Based Sirolimus-Eluting Stents With Differing Elution and Absorption Kinetics: The PANDA III Trial.

BACKGROUND: Whether the rate of drug elution and polymer absorption affects clinical outcomes of biodegradable polymer-based drug-eluting stents (DES) is unknown. The widely used polylactide polymer-based Excel stent (JW Medical, Weihai, China) elutes sirolimus within 180 days, and the polylactide polymer is completely absorbed within 6 to 9 months. In contrast, the poly-lactide-co-glycolide polymer-based BuMA stent (Sino Medical, Tianjin, China) elutes sirolimus within 30 days, and the poly-lactide-co-glycolide polymer is completely absorbed within 3 months. Thus, both metallic DES elute sirolimus, isolating major differences to the polymer and elution kinetics. OBJECTIVES: The goal of this study was to compare the safety and effectiveness between the BuMA sirolimus-eluting stent (SES) and Excel SES in an "all-comers" population. METHODS: PANDA III was a multicenter trial with few exclusion criteria, powered for sequential noninferiority and superiority testing. The primary endpoint was 1-year target lesion failure (TLF), a composite of cardiac death, target vessel myocardial infarction, or ischemia-driven target lesion revascularization. RESULTS: Between December 2013 and August 2014, 2,348 patients were randomly assigned to treatment with BuMA (n = 1,174) or Excel SES (n = 1,174). The 1-year primary endpoint of TLF occurred in 6.4% of patients in each group (difference: 0.06%; 95% confidence interval: 1.93% to 2.04%; pnoninferiority = 0.0003; psuperiority = 0.95). There were no significant between-group differences in any of the secondary endpoints other than the incidence of definite/probable stent thrombosis, which occurred less frequently with the BuMA stent (0.5% vs. 1.3%; log-rank p = 0.048). CONCLUSIONS: The BuMA SES was demonstrated to be noninferior to the Excel SES for 1-year TLF, with a lower incidence of stent thrombosis. (Comparison of BuMA eG Based BioDegradable Polymer Stent With EXCEL Biodegradable Polymer Sirolimus-eluting Stent in "Real-World" Practice [PANDA-III]; NCT02017275).